The market has climbed 1.4% in the last 7 days and 26% over the past year, with earnings expected to grow by 19% per annum in the coming years. Investing in penny stocks — though a term from earlier market days — can still offer surprising value, particularly when these stocks are backed by strong financial health. By focusing on those with robust balance sheets and clear growth potential, investors may find opportunities among smaller companies that promise both stability and upside potential.

Let's explore several standout options from the results in the screener.

Cerus (CERS)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Cerus Corporation is a biomedical products company with a market capitalization of approximately $541 million.

Operations: The company generates revenue primarily from its Blood Safety segment, totaling $216.56 million.

Market Cap: $541M

Cerus Corporation, with a market cap of US$541 million, has shown resilience in the penny stock arena despite its unprofitable status. The company's recent inclusion in the S&P Healthcare Equipment Select Industry Index highlights its growing industry presence. Cerus has secured a new debt facility with MidCap Financial, potentially reducing annual cash interest expenses by US$3.5 million and enhancing financial flexibility. While it faces challenges such as high volatility and increased debt-to-equity ratio over five years, Cerus's seasoned management team and robust cash runway position it for potential future growth amidst ongoing investor scrutiny over governance issues.

Myriad Genetics (MYGN)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Myriad Genetics, Inc. is a molecular diagnostics and precision medicine company that develops molecular tests, with a market cap of approximately $428.79 million.

Operations: The company generates revenue primarily from its biotechnology segment, which amounts to $829 million.

Market Cap: $428.79M

Myriad Genetics, with a market cap of US$428.79 million, is navigating the penny stock landscape while facing profitability challenges. Despite being unprofitable and experiencing increased losses over the past five years, Myriad maintains a strong cash position, covering both short-term and long-term liabilities. Recent strategic moves include filing for shelf registrations worth US$90.53 million and appointing Raj Jampa as CTO to enhance technological capabilities through AI integration. The company is actively showcasing its diagnostic innovations at major conferences, emphasizing its Precise MRD test's potential in cancer treatment monitoring across multiple tumor types, which could drive future growth prospects.

Summing It All Up

• Explore the 334 names from our US Penny Stocks screener here.
• Seeking Other Investments? Outshine the giants: these 14 early-stage AI stocks could fund your retirement.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.